Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alexidine dihydrochloride is a bis-biguanide compound with broad-spectrum antimicrobial properties. It exhibits potent antifungal and antibiofilm activity against a diverse range of fungal pathogens—including multidrug-resistant species such as Candida auris—and has demonstrated synergy with other antifungals like fluconazole and amphotericin B. In addition to its antifungal effects, it acts as an antibacterial agent used in endodontic procedures and is structurally related to chlorhexidine. Mechanistically, alexidine dihydrochloride is an inhibitor of protein tyrosine phosphatase localized to mitochondrion 1 (PTPMT1), which may have implications for apoptosis induction and anticancer activity. Its ability to disrupt biofilms makes it a candidate for repurposing as a pan-antifungal drug[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alexidine dihydrochloride.